论文部分内容阅读
目的:研究肺心平对肺心病肺动脉高压大鼠肺动脉ET和NOSmRNA基因表达的影响,探讨其治疗肺心病肺动脉高压的作用机制。方法:以2%野百合碱按60mg/kg一次性腹腔注射,复制大鼠肺心病肺动脉高压模型,用逆转录PCR技术检测肺动脉ET和NOSmRNA表达。结果:模型组与正常空白对照组比较肺动脉ETmRNA表达增加,NOSmRNA表达减少,中药肺心平组和卡托普利组与模型组比较,肺动脉ETmRNA表达减少,肺动脉NOSmRNA表达增加。结论:肺心平对肺心病肺动脉高压有着较好的治疗作用,其可能的作用机制是肺心平能使肺心病肺动脉高压大鼠肺动脉ETmRNA表达下降,NOSmRNA表达增加。
Objective: To study the effect of Feixinping on gene expression of ET and NOS mRNA in pulmonary artery of pulmonary hypertension rats and to explore its mechanism of action in treating pulmonary hypertension with pulmonary heart disease. METHODS: Pulmonary hypertension in rats with pulmonary heart disease was replicated by a single intraperitoneal injection of 2% monocrotaline at a dose of 60 mg/kg. The expression of ET and NOS mRNA in pulmonary artery were detected by reverse transcription PCR. Results: Compared with the normal control group, the expression of ETmRNA in the pulmonary artery was increased and the expression of NOSmRNA was decreased in the model group and the normal control group. Compared with the model group, the expression of ETmRNA in the pulmonary artery was decreased and the expression of NOSmRNA in the pulmonary artery was increased in the Chinese medicine Feixinping group and the captopril group. Conclusion: Feixinping has a good therapeutic effect on pulmonary hypertension of pulmonary heart disease. Its possible mechanism is that the level of ETmRNA in the pulmonary artery of rats with pulmonary heart disease and pulmonary hypertension is decreased and the expression of NOSmRNA is increased.